Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
10 2021
Historique:
received: 14 06 2021
accepted: 07 09 2021
revised: 18 10 2021
pubmed: 5 10 2021
medline: 15 12 2021
entrez: 4 10 2021
Statut: epublish

Résumé

Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no Email List Invitation to see which approach resulted in the highest patient satisfaction with how the results were communicated. We carried out a cluster randomised, 2 by 2 by 2 factorial, nonblinded study within a trial, with semistructured qualitative interviews with some patients (ISRCTN96189403). Each cluster was a UK hospital participating in the ICON8 ovarian cancer trial. Interventions were shared with 384 ICON8 participants who were alive and considered well enough to be contacted, at 43 hospitals. Hospitals were allocated to share results with participants through one of the 8 intervention combinations based on random permutation within blocks of 8, stratified by number of participants. All interventions contained a written plain English summary of the results. The Enhanced Webpage also contained a short video. Both the Enhanced Webpage and Email contained links to further information and support. The Mailed Printed Summary was opt-out. Follow-up questionnaires were sent 1 month after patients had been offered the interventions. Patients' reported satisfaction was measured using a 5-point scale, analysed by ordinal logistic regression estimating main effects for all 3 interventions, with random effects for site, restricted to those who reported receiving the results and assuming no interaction. Data collection took place in 2018 to 2019. Questionnaires were sent to 275/384 randomly selected participants and returned by 180: 90/142 allocated Basic Webpage, 90/133 Enhanced Webpage; 91/141 no Mailed Printed Summary, 89/134 Mailed Printed Summary; 82/129 no Email List Invitation, 98/146 Email List Invitation. Only 3 patients opted out of receiving the Mailed Printed Summary; no patients signed up to the email list. Patients' satisfaction was greater at sites allocated the Mailed Printed Summary, where 65/81 (80%) were quite or very satisfied compared to sites with no Mailed Printed Summary 39/64 (61%), ordinal odds ratio (OR) = 3.15 (1.66 to 5.98, p < 0.001). We found no effect on patient satisfaction from the Enhanced Webpage, OR = 1.47 (0.78 to 2.76, p = 0.235) or Email List Invitation, OR = 1.38 (0.72 to 2.63, p = 0.327). Interviewees described the results as interesting, important, and disappointing (the ICON8 trial found no benefit). Finding out the results made some feel their trial participation had been more worthwhile. Regardless of allocated group, patients who received results generally reported that the information was easy to understand and find, were glad and did not regret finding out the results. The main limitation of our study is the 65% response rate. Nearly all respondents wanted to know the results and were glad to receive them. Adding an opt-out Mailed Printed Summary alongside a webpage yielded the highest reported satisfaction. This study provides evidence on how to share results with other similar trial populations. Further research is needed to look at different results scenarios and patient populations. ISRCTN: ISRCTN96189403.

Sections du résumé

BACKGROUND
Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no Email List Invitation to see which approach resulted in the highest patient satisfaction with how the results were communicated.
METHODS AND FINDINGS
We carried out a cluster randomised, 2 by 2 by 2 factorial, nonblinded study within a trial, with semistructured qualitative interviews with some patients (ISRCTN96189403). Each cluster was a UK hospital participating in the ICON8 ovarian cancer trial. Interventions were shared with 384 ICON8 participants who were alive and considered well enough to be contacted, at 43 hospitals. Hospitals were allocated to share results with participants through one of the 8 intervention combinations based on random permutation within blocks of 8, stratified by number of participants. All interventions contained a written plain English summary of the results. The Enhanced Webpage also contained a short video. Both the Enhanced Webpage and Email contained links to further information and support. The Mailed Printed Summary was opt-out. Follow-up questionnaires were sent 1 month after patients had been offered the interventions. Patients' reported satisfaction was measured using a 5-point scale, analysed by ordinal logistic regression estimating main effects for all 3 interventions, with random effects for site, restricted to those who reported receiving the results and assuming no interaction. Data collection took place in 2018 to 2019. Questionnaires were sent to 275/384 randomly selected participants and returned by 180: 90/142 allocated Basic Webpage, 90/133 Enhanced Webpage; 91/141 no Mailed Printed Summary, 89/134 Mailed Printed Summary; 82/129 no Email List Invitation, 98/146 Email List Invitation. Only 3 patients opted out of receiving the Mailed Printed Summary; no patients signed up to the email list. Patients' satisfaction was greater at sites allocated the Mailed Printed Summary, where 65/81 (80%) were quite or very satisfied compared to sites with no Mailed Printed Summary 39/64 (61%), ordinal odds ratio (OR) = 3.15 (1.66 to 5.98, p < 0.001). We found no effect on patient satisfaction from the Enhanced Webpage, OR = 1.47 (0.78 to 2.76, p = 0.235) or Email List Invitation, OR = 1.38 (0.72 to 2.63, p = 0.327). Interviewees described the results as interesting, important, and disappointing (the ICON8 trial found no benefit). Finding out the results made some feel their trial participation had been more worthwhile. Regardless of allocated group, patients who received results generally reported that the information was easy to understand and find, were glad and did not regret finding out the results. The main limitation of our study is the 65% response rate.
CONCLUSIONS
Nearly all respondents wanted to know the results and were glad to receive them. Adding an opt-out Mailed Printed Summary alongside a webpage yielded the highest reported satisfaction. This study provides evidence on how to share results with other similar trial populations. Further research is needed to look at different results scenarios and patient populations.
TRIAL REGISTRATION
ISRCTN: ISRCTN96189403.

Identifiants

pubmed: 34606495
doi: 10.1371/journal.pmed.1003798
pii: PMEDICINE-D-21-02611
pmc: PMC8523080
doi:

Banques de données

ISRCTN
['ISRCTN96189403']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003798

Subventions

Organisme : Cancer Research UK
ID : 12127
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU12023/24
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/08
Pays : United Kingdom

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: AS, ECJ, CP, CT, CS, AM, AJC, NJH, CDM, KG, TI, BEB and WJC have nothing to declare. MRS reports grants and non-financial support from Astellas, grants from Clovis, grants and non-financial support from Janssen, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, grants and non-financial support from Sanofi, personal fees from Lilly Oncology, personal fees from Janssen, outside the submitted work.

Références

Clin Med (Lond). 2009 Oct;9(5):415-6
pubmed: 19886097
Health Expect. 2010 Sep;13(3):323-30
pubmed: 19906214
Expert Rev Clin Pharmacol. 2012 Mar;5(2):149-56
pubmed: 22390557
BMJ. 1998 Jul 4;317(7150):21-6
pubmed: 9651262
Trials. 2011 Jun 14;12:148
pubmed: 21672204
Clin Trials. 2011 Jun;8(3):330-41
pubmed: 21730081
Breast Cancer Res Treat. 2009 May;115(1):123-9
pubmed: 18543100
Clin Trials. 2016 Dec;13(6):574-581
pubmed: 27559022
Control Clin Trials. 1993 Dec;14(6):500-10
pubmed: 8119065
BMJ. 2019 Nov 4;367:l6324
pubmed: 31685487
J Clin Oncol. 2009 Feb 20;27(6):878-83
pubmed: 19164211
Eur J Oncol Nurs. 2011 Apr;15(2):124-9
pubmed: 20674498
J Natl Cancer Inst. 2004 Apr 21;96(8):629-32
pubmed: 15100341
Arch Neurol. 2008 Dec;65(12):1590-5
pubmed: 19064746
Br J Cancer. 2010 Mar 30;102(7):1081-4
pubmed: 20197767
BMJ. 2017 Jul 14;358:j3064
pubmed: 28710062
Lancet. 2019 Dec 7;394(10214):2084-2095
pubmed: 31791688
Health Technol Assess. 2014 Jul;18(42):1-410
pubmed: 24987820
Clin Trials. 2016 Dec;13(6):582-591
pubmed: 27562368
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
BMJ. 2006 Jan 28;332(7535):206-10
pubmed: 16401631
BMJ Open. 2019 Oct 21;9(10):e032701
pubmed: 31636111
Trials. 2020 Aug 1;21(1):694
pubmed: 32738919
PLoS Med. 2008 May 13;5(5):e91
pubmed: 18479180
Trials. 2010 Dec 01;11:116
pubmed: 21122094
Lancet. 2005 Mar 12-18;365(9463):963-4
pubmed: 15766998
J Pediatr Orthop. 2009 Jul-Aug;29(5):467-75
pubmed: 19568019
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970

Auteurs

Annabelle South (A)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Nalinie Joharatnam-Hogan (N)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Cara Purvis (C)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Elizabeth C James (EC)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Carlos Diaz-Montana (C)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

William J Cragg (WJ)

Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.

Conor Tweed (C)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Archie Macnair (A)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Matthew R Sydes (MR)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Claire Snowdon (C)

London School of Hygiene and Tropical Medicine, London, United Kingdom.

Katie Gillies (K)

Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom.

Talia Isaacs (T)

UCL Institute of Education, University College London, London, United Kingdom.

Barbara E Bierer (BE)

Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

Andrew J Copas (AJ)

MRC CTU at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH